The United States Food and Drug Administration (US FDA) has approved VYKAT™ XR, a significant milestone as the first approved treatment for hyperphagia in Prader-Willi syndrome (PWS).

Protagonist (Nasdaq: PTGX) is one of a handful of Bay Area drug developers ready to ask the Food and Drug Administration to ...

Over the last 7 days, the United States market has dropped 3.4%, yet it remains up by 6.1% over the past year, with earnings anticipated to grow by 14% annually in the coming years. In this context, ...

Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on Soleno Therapeutics (SLNO – Research Report) today and set a price target of ...

Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO – Get Free Report) saw unusually-high trading volume on Monday after HC ...

Soleno Therapeutics, Inc. (NASDAQ:SLNO – Get Free Report) shares were up 3.9% during trading on Friday after Stifel Nicolaus ...

We recently published a list of 10 Stocks Outperform Broader Market Last Week. In this article, we are going to take a look ...

US FDA approves Soleno Therapeutics’ Vykat XR to treat hyperphagia in Prader-Willi syndrome: Redwood City, California Saturday, March 29, 2025, 18:00 Hrs [IST] Soleno Therapeuti ...

We recently published a list of 10 Firms End Friday Strong; 3 Reach All-Time Highs. In this article, we are going to take a ...

Shares of the Redwood City-based Soleno Therapeutics climbed 38% — the biggest one-day gain since September 2023 — to their ...

We recently published a list of 10 Stocks Jump, Defy Market Uncertainties on Thursday. In this article, we are going to take ...